Bresnahan pointed out that community pharmacy needs to diversify,“ to respond to the market shifts, [particularly] as traditional prescription volume starts to shift away from traditional retail pharmacy.”
The paper concludes that, although the negotiation program might reduce drug costs initially, it could threaten the long-term sustainability of the generics and biosimilars market, a key driver of lower prescription costs.
Dave’s Pharmacy delivers innovative clinical services—including point-of-care testing and remote patient monitoring—to elevate patient care.
Buddy Carter is spearheading along with 11 bipartisan members of Congress, including Diana Harshbarger, in introducing the PBM Reform Act, which protects patients and pharmacies from the harmful and anticompetitive business practices of PBMs.
With limited treatment options available to people living with severe alopecia areata in the U.S., the need for innovative therapies such as Leqselvi remains critically important.
This investment furthers Cardinal Health's longstanding advocacy around the future of independent pharmacies and ongoing partnerships with industry organizations to support pharmacists' efforts to build relationships with elected officials at all levels of government.
Systemic changes like those in the PBM Reform Act must pass and be enacted as soon as possible. We’re grateful for this bill’s introduction and will do everything we can to push it across the finish line.”
The bill establishes powerful transparency requirements, bans spread pricing, assures fair reimbursement for pharmacies, and tackles anti-competitive practices that have driven up drug costs and limited patient choice.
White paper analyzes problems and solutions to patent abuses.
The program will be anchored by IPC’s iCare+ Independent Pharmacy Network, which includes thousands of community-rooted pharmacies nationwide and many in New Jersey.
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases.
Ipratropium bromide nasal solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals.
"This lawsuit centered on a highly technical prescription dispensing record keeping issue that was allowed by law in many states," CVS said in a statement.
39 Groups support the Biosimilar Red Tape Elimination Act.
Millions of patients using GLP-1 drugs for weight loss could see costs skyrocket.
The policy would have prevented PBMs from having their compensation linked to the list prices of medications.
